ZyVersa Q3 net loss $2.4M, cash only $0.1M; Phase 2a trial expected Q1 2025

ZyVersa Therapeutics, Inc.

2024-Q3 EPS reported -$9.79 vs consensus -$3.77 ▼ miss (-159.4%)

Net loss improved 17.3% to $2.4M from $2.9M YoY; R&D and G&A expenses decreased.
Cash at Sept 30, 2024: $0.1M; company will need additional financing on a month-to-month basis.
Phase 2a trial for VAR 200 in diabetic kidney disease expected to begin Q1 2025 with data mid-2025.
IC 100 IND submission planned for Q2 2025; Phase 1 trial in overweight subjects planned Q2/Q3 2025.
Raised ~$3.9M from Q3 2024 to present; formed new Obesity, Metabolic & Inflammatory Disease SAB.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.